Holen Sie sich die Stockscreener-App
13.17
0.00%
0.00
Vorhandelsmarkt:
13.54
0.37
+2.81%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$13.17
Offen:
$13.1
24-Stunden-Volumen:
3.71M
Relative Volume:
1.95
Marktkapitalisierung:
$1.73B
Einnahmen:
$260.11M
Nettoeinkommen (Verlust:
$60.64M
KGV:
30.63
EPS:
0.43
Netto-Cashflow:
$92.29M
1W Leistung:
+7.16%
1M Leistung:
+16.04%
6M Leistung:
+60.41%
1J Leistung:
+79.92%
1-Tages-Spanne:
$12.79
$13.49
1-Wochen-Bereich:
$11.96
$13.49
52-Wochen-Spanne:
$6.55
$13.54
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Firmenname
Aurinia Pharmaceuticals Inc
Sektor
Branche
Telefon
250-744-2487
Adresse
#140, 14315 - 118 AVENUE, EDMONTON, BC
Vergleichen Sie AUPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
13.17 | 1.73B | 260.11M | 60.64M | 92.29M | 0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-05-05 | Eingeleitet | Cowen | Outperform |
| 2020-01-10 | Eingeleitet | Jefferies | Buy |
| 2019-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-16 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-10-30 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Bestätigt | FBR & Co. | Outperform |
| 2016-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2016-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-08 | Eingeleitet | MLV & Co | Buy |
Alle ansehen
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
Aurinia: Q3 Earnings Snapshot - News-Times
Aurinia Pharmaceuticals Inc $AUPH Shares Bought by Hussman Strategic Advisors Inc. - MarketBeat
Aurinia Pharmaceuticals Q3 profit doubles on strong LUPKYNIS sales, raises FY sales view - MarketScreener
Aurinia Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress - Bluefield Daily Telegraph
Aurinia Pharmaceuticals Doubles Profit As Lupkynis Sales Jump - Finimize
Is Aurinia Pharmaceuticals Inc. stock positioned well for digital economyTrend Reversal & Safe Capital Growth Trade Ideas - newser.com
FDA CDER Head Janet Tidmarsh Removed Amid Aurinia Pharmaceuticals Lawsuit Alleging Misconduct - geneonline.com
FDA Official Quits As Aurinia Sues Over 'Personal Vendetta' - Law360
FDA’s top drug regulator sued by drug company, resigns amid conduct probe - The Hill
Aurinia Pharmaceuticals Reportedly Files Lawsuit Against US FDA Official - MarketScreener
US FDA's drug division chief resigns amid ethics concerns and lawsuit - Reuters
FDA’s Top Drug Regulator Resigns, Agency Cites Personal Conduct - Bloomberg.com
Strategies to average down on Aurinia Pharmaceuticals Inc.2025 Analyst Calls & Consistent Growth Equity Picks - newser.com
Will Aurinia Pharmaceuticals Inc. stock recover faster than marketGlobal Markets & Weekly Stock Breakout Alerts - newser.com
Aurinia Pharmaceuticals Inc expected to post earnings of 16 cents a shareEarnings Preview - TradingView
Key metrics from Aurinia Pharmaceuticals Inc.’s quarterly data2025 Bull vs Bear & Expert-Curated Trade Recommendations - newser.com
Wall Street Breakfast Podcast: FDA Executive Controversy (undefined:AUPH) - Seeking Alpha
Is Aurinia Pharmaceuticals Inc. building a consolidation baseJuly 2025 Snapshot & AI Powered Trade Plan Recommendations - newser.com
Why Aurinia Pharmaceuticals Inc. is moving todayQuarterly Portfolio Report & Smart Money Movement Alerts - newser.com
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 - Business Wire
Aurinia Pharmaceuticals To Report Q3 Results, Provide Update On Recent Business Progress On November 4 - TradingView
Can Aurinia Pharmaceuticals Inc. stock reach $100 price targetRecession Risk & Low Drawdown Investment Ideas - newser.com
PRESS DIGEST-Wall Street JournalNovember 3 - facilitiesmanagement-now.com
Analyzing drawdowns of Aurinia Pharmaceuticals Inc. with statistical toolsWeekly Trend Summary & Long-Term Capital Growth Ideas - newser.com
Is Aurinia Pharmaceuticals Inc. reversing from oversold territoryMarket Movement Recap & Free Weekly Watchlist of Top Performers - newser.com
Using data models to predict Aurinia Pharmaceuticals Inc. stock movementDip Buying & Free Reliable Trade Execution Plans - newser.com
Combining price and volume data for Aurinia Pharmaceuticals Inc.Weekly Trading Summary & Daily Profit Focused Stock Screening - newser.com
F.D.A. Drug Unit Chief Resigns, and Is Sued by Drug Company - The New York Times
Top FDA official Tidmarsh resigns after comments on kidney drug, HHS probe - Seeking Alpha
FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ - Stocktwits
Is Aurinia Pharmaceuticals Inc. (IKAP) stock undervalued historicallyMarket Growth Summary & Free High Return Stock Watch Alerts - newser.com
FDA Official Steps Down, Sued by DrugmakerWSJ - The Wall Street Journal
Will breakout in Aurinia Pharmaceuticals Inc. lead to full recoveryWeekly Earnings Recap & Free Expert Approved Momentum Trade Ideas - newser.com
What analysts say about Aurinia Pharmaceuticals Inc IKAP stockMACD Trading Signals & Double Digit Wealth Tips - earlytimes.in
Visualizing Aurinia Pharmaceuticals Inc. stock with heatmaps2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com
Chart overlay techniques for tracking Aurinia Pharmaceuticals Inc.Market Performance Summary & Community Consensus Picks - newser.com
Using R and stats models for Aurinia Pharmaceuticals Inc. forecastingProfit Target & Weekly Market Pulse Alerts - newser.com
Is There An Opportunity With Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 49% Undervaluation? - 富途牛牛
Aurinia Pharmaceuticals (AUPH) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Finanzdaten der Aurinia Pharmaceuticals Inc-Aktie (AUPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aurinia Pharmaceuticals Inc-Aktie (AUPH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Director |
Aug 05 '25 |
Buy |
11.68 |
200,000 |
2,336,000 |
11,329,500 |
| TANG KEVIN | Director |
Aug 04 '25 |
Buy |
11.34 |
100,000 |
1,134,000 |
11,129,500 |
| Keenan Greg | Chief Medical Officer |
Aug 01 '25 |
Sale |
10.50 |
20,000 |
210,000 |
133,484 |
| Keenan Greg | Chief Medical Officer |
Mar 07 '25 |
Sale |
8.23 |
8,305 |
68,350 |
153,484 |
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):